Patient Outcomes of Rezvilutamide vs Bicalutamide in Prostate Cancer
Author Information
Author(s): Wang Hongkai, Jiang Shusuan, Luo Hong, Zhou Fangjian, He Dalin, Ma Lulin, Guo Hongqian, Liang Chaozhao, Chong Tie, Jiang Jun, Chen Zhiwen, Wang Yong, Zou Qing, Tian Ye, Xiao Jun, Huang Jian, Chen Jinchao, Dong Qiang, Zhang Xiaoping, Li Hanzhong, Yang Xinfeng, Lian Jianpo, Wang Wenliang, Ye Dingwei
Primary Institution: Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
Hypothesis
Does rezvilutamide combined with androgen deprivation therapy improve patient-reported outcomes compared to bicalutamide in high-volume metastatic hormone-sensitive prostate cancer patients?
Conclusion
Rezvilutamide combined with androgen deprivation therapy significantly improves pain management and functional outcomes compared to bicalutamide in patients with high-volume metastatic hormone-sensitive prostate cancer.
Supporting Evidence
- Patients treated with rezvilutamide experienced a longer time to progression of worst pain intensity compared to those on bicalutamide.
- Rezvilutamide showed a significant delay in the deterioration of functional health as measured by the FACT-P questionnaire.
- Both treatment groups had comparable baseline characteristics, ensuring a fair comparison.
Takeaway
This study shows that a new medicine called rezvilutamide helps people with prostate cancer feel less pain and stay active longer than an older medicine called bicalutamide.
Methodology
Patients were randomly assigned to receive either rezvilutamide or bicalutamide with androgen deprivation therapy, and patient-reported outcomes were assessed using specific questionnaires.
Potential Biases
Potential bias due to the study being conducted in a specific demographic and the exploratory nature of patient-reported outcomes.
Limitations
The follow-up duration may not fully capture long-term patient-reported outcomes, and the study population was predominantly Asian, which may limit generalizability.
Participant Demographics
Patients were men aged 18 and older with high-volume metastatic hormone-sensitive prostate cancer, primarily Asian.
Statistical Information
P-Value
p=0.002
Confidence Interval
95% CI 7.4–20.3
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website